December 5, 2012
Journal for ImmunoTherapy of Cancer - Call for Papers
I’m pleased to announce that the Society for Immunotherapy of Cancer (SITC) is now accepting submissions for its new online, open access peer-reviewed journal, the Journal for ImmunoTherapy of Cancer (JITC), in the following categories:
• Basic Tumor Immunology
• Clinical/Translational Cancer Immunotherapy
• Immunotherapy Biomarkers
• Reviews/Editorials
Recently the field of cancer immunology and immunotherapy has seen a tremendous increase in excitement and momentum, brought about by the latest approvals of immunotherapy-based treatments in various cancer types. Such levels of activity require the appropriate resources to share new knowledge and catalyze the development of the field. To fulfil this need and enrich communication between the many stakeholders in the tumor immunology and cancer immunotherapy community, SITC created the Journal for ImmunoTherapy of Cancer to serve as a targeted outlet for the publication of original research articles, literature reviews, opinion/position papers and a forum to discuss the hot issues in tumor immunology and cancer immunotherapy research. An editorial board formed with outstanding leaders in both basic and clinical tumor immunology and cancer immunotherapy fields is ready to process your manuscripts and steer the journal in its initial stages in close collaboration with SITC.
On behalf of the Society for Immunotherapy of Cancer, I encourage you to submit your research to the Journal for ImmunoTherapy of Cancer and take advantage of an efficient online submission process; a rapid, high quality peer-review service; and immediate publication upon acceptance. There are no color charges and no limits on the number of figures or embedded movies.
The Journal for ImmunoTherapy of Cancer will be included in freely accessible full text repositories. This complies with the open access policies of many funders including those of the Howard Hughes Medical Institute, NIH, and Wellcome Trust.
Finally, as a way to say thank you to the dedicated Society members who work tirelessly to advance the science and ultimately to improve the lives of patients with cancer, SITC is pleased to offer waived article processing charges for Society members through the end of 2013. To take advantage of this member benefit, or to become a SITC member, please contact the SITC Executive Office for more information (Ph: +414-271-2456, Email: info@sitcancer.org).
Yours sincerely,
Pedro Romero,
The Editor-in-Chief
Journal for ImmunoTherapy of Cancer
* The Society for Immunotherapy of Cancer (SITC) was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of immunotherapy for patients with cancer. Society members include nearly 600 influential leaders and scientists engaged in cancer immunology and immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC’s members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer. Please visit the Society website, www.sitcancer.org, for more information about SITC.
